Bruker (NASDAQ:BRKR) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Posted by Francis Steltz on Nov 5th, 2026

Bruker (NASDAQ:BRKR – Get Free Report) posted its quarterly earnings results on Wednesday. The medical research company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.14, FiscalAI reports. The business had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. Bruker’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the company posted $0.45 earnings per share.

Here are the key takeaways from Bruker’s conference call:

Margins and adjusted EPS improved sharply: Q3 non-GAAP operating margin rose 400 basis points to 16.3%, and diluted non-GAAP EPS increased 24% to $0.56, helped by cost savings and favorable product mix.
Bookings point to improving demand: BSI book-to-bill remained above one for a fifth consecutive quarter, with year-to-date bookings and backlog up mid-single digits. Management cited strong China demand, a return to U.S. academic and government bookings growth, and more than 30% year-to-date growth in semiconductor metrology orders.
Bruker reaffirmed its 2026 organic revenue growth outlook of 1%–2% and non-GAAP EPS range of $2.10–$2.15; it expects lower-mid-single-digit organic revenue growth in Q4. Management said 2027 should bring faster organic growth, further margin expansion, and double-digit EPS growth, while noting detailed guidance will come in February.
Reported growth remained modest: Q3 organic revenue increased just 0.7%, while BSI organic revenue declined 0.4%, partly due to previously disclosed semiconductor instrument pushouts. GAAP results included a roughly $175 million non-cash goodwill impairment tied to Bruker Spatial Biology and a diluted loss per share of $0.81.

Bruker Price Performance

BRKR traded down $4.38 during trading on Thursday, hitting $59.41. 521,091 shares of the stock traded hands, compared to its average volume of 2,370,364. The business has a 50 day moving average price of $58.95 and a 200 day moving average price of $50.48. The company has a market cap of $9.05 billion, a price-to-earnings ratio of -85.84, a PEG ratio of 1.73 and a beta of 1.26. Bruker has a twelve month low of $32.37 and a twelve month high of $68.98. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, September 21st. Bruker’s dividend payout ratio is -28.57%.

Key Bruker News

Here are the key news stories impacting Bruker this week:

Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, versus $0.42 expected, and revenue of $874 million, above the $865.2 million consensus. Earnings also rose from $0.45 a year earlier. Bruker Q3 Earnings and Revenues Surpass Estimates
Positive Sentiment: Management highlighted margin expansion, strong bookings and returning demand from U.S. academic customers—potential signs of improving operating momentum. The company also targeted double-digit EPS growth in fiscal 2027. Bruker Q3 2026 Earnings Call Highlights
Neutral Sentiment: Full-year 2026 guidance was close to expectations: revenue of $3.52 billion–$3.56 billion versus a $3.56 billion estimate, and non-GAAP EPS of $2.10–$2.15 versus $2.12 expected. Bruker Full-Year Revenue Guidance
Negative Sentiment: Revenue grew just 1.6% year over year, and coverage pointed to a steep goodwill charge that offset the positive operating results. Reports described an 8.7% drop on earnings day, suggesting investors were concerned about the quality or durability of growth despite the headline beat. Bruker Drops on Q3 Earnings Report Day

Analysts Set New Price Targets

A number of brokerages recently commented on BRKR. Leerink Partners upped their price target on shares of Bruker from $60.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Stifel Nicolaus set a $50.00 price objective on Bruker in a report on Wednesday, August 5th. Guggenheim boosted their price objective on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. JPMorgan Chase & Co. downgraded Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research report on Wednesday, October 14th. Finally, Citigroup lowered their target price on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus price target of $59.43.

Get Our Latest Stock Analysis on BRKR

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president directly owned 134,806 shares in the company, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.20% of the stock is owned by company insiders.

About Bruker

(Get Free Report)

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.